Dr. Induru Discusses Other Mutations in Lung Cancer

Raghava R. Induru, MD
Published: Monday, Nov 20, 2017



Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

EGFR, ALK, and ROS1, are the most well-known molecular subtypes of lung cancer, and have been used to develop effective treatments, but there are other targets that may help guide treatment.

Of these other targets, BRAF mutations and NTRK mutations are most notable, says Induru. The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is FDA approved for BRAF-mutated tumors, and entrectinib is showing promise in NTRK-mutated tumors.
 


Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

EGFR, ALK, and ROS1, are the most well-known molecular subtypes of lung cancer, and have been used to develop effective treatments, but there are other targets that may help guide treatment.

Of these other targets, BRAF mutations and NTRK mutations are most notable, says Induru. The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is FDA approved for BRAF-mutated tumors, and entrectinib is showing promise in NTRK-mutated tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x